Conditions: Non-small Cell Lung Cancer
Keywords: Advanced stage
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 19
Healthy volunteers: no

Brief summary:
The purpose of this study is to determine the efficacy and the toxicities of the study drug PD0332991 in the treatment of patients with Stage IV non-small cell lung cancer with wildtype retinoblastoma protein (RB) and inactivated cyclin dependent kinase (CDK) N2A in the tumor.

Detailed description:
The oral drug PD0332991 is a highly selective reversible inhibitor of cyclin-dependent kinases 4 \& 6 that is being studied for use in the treatment of advanced non-small cell lung cancer.

Arms:
arm 1: PD0332991 125 mg PO days 1 - 21

Interventions: intervention 1: PD0332991
Intervention descriptions: intervention 1: PD0332991 125 mg PO days 1 - 21

Protocol document: